Sensa supports weight-loss claims
This article was originally published in The Tan Sheet
Executive Summary
Supplement marketer Sensa Products substantiates claims its weight-loss product Sensa "works with your body's natural impulses" and "was proven effective in one of the largest clinical studies ever performed on a non-prescription weight-loss product," the National Advertising Division says in a report Sept. 3. The Council of Better Business Bureaus division notes a clinical study of the weight-loss product included 1,436 participants who lost an average of 30.5 pounds in six months as advertised. NAD recommends the firm discontinue testimonials on Sensa's Web site that say people who took Sensa lost 70 or 120 pounds. NAD says the testimonials are misleading when paired with claims based on studies. Manhattan Beach, Calif.-based Sensa says it will consider NAD's recommendation
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.